Cathelicidins are a class of small cationic peptide antibiotics that are expressed in skin and in other epithelial cells and are an active component of mammalian innate immunity. Human cathelicidin (hCAP18/LL-37) consists of a conserved prosequence called the cathelinlike domain and a C-terminal peptide named LL-37. To date, our understanding of the cathelin-like domain was very limited. To bring insight into the function of this evolutionarily conserved prosequence, we produced recombinant human cathelin-like protein and full-length hCAP18/LL-37 in Escherichia coli. As the cathelin-like protein shares homology with the cystatin family of cysteine protease inhibitors, we ¢rst analyzed the e¡ect of the cathelin-like recombinant protein on the cysteine protease cathepsin L. We found that the cathelin-like protein inhibited protease activity. Next, we tested the cathelin-like protein for antimicrobial activity using solid phase radial di¡usion and liquid phase killing assays. The cathelin-like prosequence, but not full-length hCAP18/LL-37, killed human pathogens including E. coli and methicillin-resistant Staphylococcus aureus at concentrations ranging from 16 to 32 lM. Together these ¢ndings suggest that after proteolytic cleavage the cathelin-like domain can contribute to innate host defense through inhibition of bacterial growth and limitation of cysteine-proteinase-mediated tissue damage. As these dual functions are complementary to the LL-37 peptide released from the C-terminus of full-length hCAP18/LL-37, human cathelicidin represents an elegant multifunctional e¡ector molecule for innate immune defense of the skin.
S mall, cationic antimicrobial peptides (AMPs) are naturally occurring antibiotics of the innate immune system. AMPs are widely distributed in animals and plants and are among the most ancient host defense factors (Ho¡mann et al, 1999) . Their spectrum of activity includes Gram-positive and Gram-negative bacteria as well as fungi and certain viruses (Boman, 2000; Zaslo¡, 2002) . As resistance of pathogenic microbes to conventional antibiotics increases, researchers are exploring these endogenous antibiotics as a potential source for new therapies against a variety of infectious diseases. In humans, there are several classes of known AMPs including adefensins, b-defensins, and cathelicidins. Cathelicidins are found in several mammalian species and accumulating evidence supports a key role for this class of AMPs in innate immune defense (for review see Gennaro and Zanetti, 2000; Ramanathan et al, 2002; Zaiou and Gallo, 2002) . Recently, development and characterization of a cathelicidin knockout mouse provided evidence that endogenous expression of an AMP protects the host against invasive bacterial infection of the skin (Nizet et al, 2001) . Additional investigations have identi¢ed roles for cathelicidins in speci¢c clinical disease states. Production of cathelicidins is induced in response to epithelial wounding or infectious challenge (Dorschner et al, 2001; Schaller-Bals et al, 2002) , or suppressed by the virulence mechanisms of certain bacterial pathogens, e.g., Shigella dysenteriae (Islam et al, 2001 ). Cathelicidin expression is also di¡erentially a¡ected in certain chronic in£am-matory disorders. In psoriasis, cathelicidin levels are elevated and secondary infection is rare (Frohm et al, 1997) , whereas in atopic dermatitis cathelicidin expression is de¢cient and bacterial or viral superinfection is common (Ong et al, 2002) . Therapeutic bene¢ts of cathelicidin have been demonstrated experimentally, including decreased bacterial colonization of skin wounds following topical administration (Cole et al, 2001 ) and improved pulmonary bacterial clearance with cathelicidin overexpression through viral gene transfer (Bals et al, 1999a,b) .
Cathelicidin proteins are composed of two distinct domains: an N-terminal ''cathelin-like'' or ''prosequence'' domain and the C-terminal domain of the mature AMP. The highly variable C-terminal domains of cathelicidins were among the earliest mammalian AMPs to show potent, rapid, and broad-spectrum killing activity (Zanetti et al, 1990; Gennaro et al, 1998 ). In contrast, the function of the conserved prosequence domain of cathelicidins is less well understood. The term ''cathelin-like'' derives from the similarity of this sequence with that of cathelin, a 12 kDa protein isolated from porcine neutrophils that shares similarity with the cystatin superfamily of cysteine protease inhibitors (Ritonja et al, 1989; Storici et al, 1996; Scocchi et al, 1997) . Cathelicidins are expressed in neutrophils and myeloid bone marrow cells (Zanetti et al, 1990; Gallo et al, 1997; Ganz and Lehrer, 1997; Sorensen et al, 1997) and at most epithelial surfaces (Frohm et al, 1997; Harder et al, 1997; Bals et al, 1998; Dorschner et al, 2001) , and were the ¢rst AMPs discovered in mammalian skin due to their presence in wound £uid (Gallo et al, 1994) . In the neutrophil, cathelicidins are synthesized as a full-length precursor and targeted to the secondary granules where they are stored. Upon stimulation, the full-length cathelicidin protein is proteolytically processed to unleash the microbicidal activity of the C-terminal peptide from the cathelin-like domain (Zanetti et al, 1991; Sorensen et al, 2001) .
Although the killing activities and biologic functions of mature cathelicidin antimicrobial peptides have been investigated extensively, a satisfactory description and evidence of the function of the conserved cathelin-like prosequence are still unavailable. The structure of this 96^104 residue protein domain is believed to be stabilized by four cysteines engaged in two disul¢de bonds (Storici et al, 1996; Sanchez et al, 2002a,b) . These four cysteines as well as their relative positions are well conserved in all species. The strict evolutionary conservation of this domain and its similarity to cystatins, a family of proteinase inhibitors, suggests it plays a speci¢c and independent biologic function in host defense (Gennaro and Zanetti, 2000) .
To investigate possible function(s) of the cathelin-like domain, we selected the sole human cathelicidin, hCAP18/LL-37 (cationic antibacterial protein of 18 kDa). The C-terminal mature AMP of 37 amino acids (LL-37) of CAP18/LL-37 has been well characterized (Agerberth et al, 1995) . Here we report prokaryotic expression of recombinant full-length hCAP18/LL-37 and its cathelin-like prosequence. We show that the human cathelin-like domain acts as a cysteine proteinase inhibitor and discover that it exhibits antibacterial activity against pathogens including Escherichia coli and methicillin-resistant Staphylococcus aureus (MRSA). This antimicrobial activity is distinct from that of the LL-37 peptide. These ¢ndings suggest that the cathelin-like domain of hCAP18/ LL-37 is a distinct contributor to skin innate host defense through inhibition of both bacterial growth and cysteineproteinase-mediated tissue damage.
MATERIALS AND METHODS
Construction of human cathelicidin expression vectors Expression plasmids containing the human full-length cathelicidin cDNA (hCAP18/ LL-37) residues (31^170) or the cathelin-like domain residues (31^131) were constructed as fusion proteins in the pET-28a vector (Novagen, Madison, WI) using standard methods (Sambrook et al, 1989) . High¢delity polymerase chain reaction was used to amplify the coding sequence of hCAP18/LL-37 with primers designed from the published sequence (Gudmundsson et al, 1996) : forward primer P1, 5 0 -TCC-GAGCTCGACGATGACGATAAGCTGCTGGGTGATTTCTTCCGG-3 0 , containing a SacI recognition site and enterokinase cleavage site (underlined), and reverse primer P2, 5 0 -CCGCTCGAGCTAGGACTCT-GTCCTGGGTACAAGATTCCG-3 0 . For plasmid pET-Cath, we used primer P1 (above) and reverse primer P3, 5 0 -CCGCTCGAGCTACTAGG-CAAATCTCTTGTTATCCTT-3 0 . P2 and P3 both contain stop codons and XhoI restriction site extensions. SacI and XhoI digested polymerase chain reaction amplicons were used for unidirectional ligation into pET-28 vector. The pET-hCAP18 and pET-Cath constructs were con¢rmed by plasmid puri¢cation and direct DNA sequencing.
Expression of cathelicidin proteins pET-hCAP18 or pET-Cath were transformed into protease-de¢cient E. coli strain BL21 (DE3). Overnight cultures of each in Luria^Bertani broth (LB) (1% bactotryptone, 0.5% yeast extract, 1% NaCl) supplemented with kanamycin (50 mg per ml) were used to inoculate 1 l LB broth and then grown at 371C with agitation to 0.6 OD at 600 nm. Expression was induced by addition of isopropyl-b-D-thiogalactopyranoside (IPTG) to a concentration of 0.5 mM. Cells were harvested by centrifugation (6500 Â g) for 10 min at 41C and then resuspended in 50 ml ice-cold sonication bu¡er (0.1 M Tris^HCl pH 8.0; 0.01 M Na 2 HPO 4 , 0.1 M NaCl; 0.05 M ethylenediamine tetraacetic acid (EDTA); 0.005 M b-mercaptoethanol) supplemented with the protease inhibitors 0.1% aprotinin and 2 mM phenylmethylsulfonyl £uoride. Cells were disrupted by sonication on ice and the mixture was centrifuged at 20,000 Â g for 30 min to separate the insoluble material. Recombinant protein solubility was assessed by comparative sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) separation of both the supernatant and the pellet fractions. The supernatant fraction containing soluble recombinant proteins was collected and guanidine^HCl and bmercaptoethanol were added to ¢nal concentrations of 6 M and 0.1%, respectively. The pellet resulting from the centrifugation was washed with 50 mM Tris^HCl and 5 mM EDTA. Insoluble full-length hCAP18/LL-37 and cathelin-like proteins were extracted overnight at 41C with lysis bu¡er supplemented with 6 M guanidine^HCl and b-mercaptoethanol with a yield of 70%^90% without degradation. The suspension was then centrifuged at 20,000 Â g for 30 min to remove the remaining insoluble material. The supernatants of both extractions were dialyzed against 200 mM NaCl, 200 mM L-arginine, 10 mM b-mercaptoethanol, and 50 mM Tris^HCl pH 8.0, followed by extensive dialysis against 10 mM Tris^HCl pH 7.5. The solution was centrifuged for 10 min at 15,000 Â g to remove any precipitate. Proteins were pooled with the soluble fractions obtained earlier.
Puri¢cation of recombinant proteins Immobilized metal a⁄nity chromatography was employed. The supernatant was dialyzed against bu¡er A consisting of 0.5 M NaCl, 0.02 M Na 2 HPO 4 pH 7.5. Proteins were loaded onto an Ni 2 þ^N TA 5 ml His-Trap column (Pharmacia Biotech, Piscataway, NJ) previously equilibrated with bu¡er A to which 40 mM imidazole was added (£ow rate 1 ml per min). The column was washed with 50 volumes of bu¡er A containing 40 mM imidazole to remove unspeci¢c bound materials and bound proteins were eluted with 500 mM imidazole in bu¡er A, collecting 1 ml fractions. The elution pro¢le was monitored by separation of samples by SDS-PAGE. Fractions containing proteins of interest were pooled and dialyzed against 0.5 M NaCl, 0.02 M Na 2 HPO 4 pH 7.5 and the puri¢cation step was repeated at least twice. Eluted fractions were pooled and were dialyzed against enterokinase bu¡er (50 mM Tris^HCl pH 8.0, 1 mM CaCl 2 , 0.1% Tween-20).
Enterokinase digestion The upstream 43 -residue N-terminal fusion sequence of pET containing the enterokinase recognition sequence DDDDK was cleaved from the recombinant hCAP18/LL-37 and Cath proteins by digestion with enterokinase (obtained as a 1 unit per ml solution from Invitrogen, Carlsbad, CA). The reaction was incubated at 371C overnight with an enzyme:protein substrate ratio of 1:25. Digested proteins were dialyzed against 10 mM Tris^HCl pH 7.5 and then proteins were applied onto a Superdex-75 column (2.6 Â100 cm) and eluted using 10 mM phosphate bu¡er (pH 7.5) containing 150 mM NaCl at room temperature. Fractions containing proteins of interest were collected and dialyzed against 10 mM Tris^HCl pH 7.5.
SDS-PAGE and immunoblotting
The purity of cathelin-like or hCAP18/LL-37 protein was ¢rst con¢rmed by SDS-PAGE followed by Coomassie blue and silver staining. For Western blot, protein was separated by SDS-PAGE and was then transferred to nitrocellulose membranes using the Bio-Rad system. Membranes were blocked for 1 h at room temperature with 0.1% low fat milk in 50 mM Tris^HCl, pH 7.5, 150 mM NaCl, 0.2% Tween-20, and were probed overnight at 41C with chicken polyclonal anticathelin-like antibodies (1:15,000) to detect cathelin-like protein or with rabbit anti-LL-37 antibodies (1:6000) to detect full-length hCAP18/LL-37, followed by extensive washing. Immunoreactive materials were detected by enhanced chemiluminescence using horseradish peroxidase conjugated antichicken antibodies (1:20,000) or horseradish peroxidase conjugated antirabbit antibodies (1:5000).
Matrix-assisted laser desorption/ionization time of £ight (MALDI-TOF) mass spectrometry A MALDI-TOF mass spectrometer (Applied Biosystems, Framingham, MA) was used to analyze puri¢ed proteins and further con¢rm identity and purity. Protein samples were prepared for analysis by mixing in a 1:1 ratio with sinapinic acid matrix (3,5-dimethoxy-4 -hydroxycinnamic acid). Calibration was performed using internal standards: bovine insulin, apomyoglobin, and thioredoxin (Core facility at the University of California, San Diego).
Proteinase activity inhibition assay Proteinase inhibitory activity of recombinant cathelin-like protein was assayed spectro£uorometrically by measuring its inhibitory action against human liver cathepsin L (Calbiochem, CA). For the reaction assay, cathepsin L (0.1 mU) in the assay bu¡er (340 nM sodium acetate, 60 mM acetic acid, 8 mM dithiothreitol, and 4 mM EDTA, pH 5.5, supplemented with 0.1% BRIJ 35) was preincubated for 2 min at 301C with 10 À6 M cathelin-like protein before adding 20 mM of substrate Z-Phe-Arg-7-amido-4 -methylcoumarin (Calbiochem). When hydrolyzed by cathepsin L, this substrate releases highly £uorescent 7-amido-4 -methylcoumarin (AMC). AMC intensity was determined using a spectrophotometer at 370 nm excitation and an emission wavelength of 460 nm. One unit was de¢ned as the amount of enzyme that will hydrolyze 1.0 mmol of Z-Phe-Arg-AMC per min at 251C, pH 5.5.
Antimicrobial assays E. coli (ATCC 25922), Pseudomonas aeruginosa (ATCC 8427), Salmonella typhimurium (ATCC 13311), Proteus vulgaris (ATCC 8427), Staphylococcus epidermidis (ATCC 12228), and MRSA (ATCC 33591) isolates were maintained on trypticase soy broth (TSB) agar plates. Individual colonies were selected and cultured overnight in TSB, subcultured once at 1:50 in fresh TSB, and then grown to stationary phase for use in all experiments. The radial di¡usion assay was performed as described previously (Steinberg and Lehrer, 1997) in 0.5% agarose and 0.75% tryptone brought to ebullition and cooled to 431C, and then mixed with 100 ml of bacterial suspension and poured into a 10 cm Petri dish. A series of small wells (diameter, 3 mm) were punched in the plate after the agarose solidi¢ed. Two microliters of test samples were applied in each well. Plates were incubated at 371C overnight to allow visible growth of bacteria. Antibacterial activity was indicated by the clear zone (no bacterial growth) around the well.
The colony-forming assay (CFU) was performed as described previously (Valore et al, 1996) . Brie£y, bacterial cultures (E. coli or MRSA) were collected at the logarithmic phase of growth in TSB, washed twice with phosphate-bu¡ered saline, pH 7.4, and diluted to 10 4 CFU per ml in 10 mM phosphate bu¡er, pH 7.4, Na 2 HPO 4 /NaH 2 PO 4^1 % TSB (g per l). Forty-¢ve microliters of bacterial suspension were mixed with 5 ml of H 2 O (control) or with 5 ml of di¡erent concentrations of cathelin-like proteins, and the mixture was incubated at 371C. Every 30 min, a 10 ml aliquot of the reaction mixture was plated directly onto a TSB agar plate and then incubated at 371C overnight for enumeration of CFU. Data are reported as growth index ¼ ¢nal CFU/CFU in initial inoculum.
Processing of full-length hCAP18/LL-37 to cathelin-like protein and LL-37 Full-length hCAP18/LL-37 recombinant protein (10 ng) was incubated with 10 mU of human neutrophil elastase (Calbiochem) at 371C for 30 min. The sample was subsequently boiled in Laemmli sample bu¡er and run by SDS-PAGE followed by immmunoblot analysis with anticathelin-like and anti-LL37 antibodies.
RESULTS
Expression and puri¢cation of cathelicidin proteins in E. coli In this study, cathelin-like protein and full-length cathelicidin hCAP18/LL-37 proteins were required for functional analysis. In order to achieve e⁄cient expression of these proteins in E. coli, cDNA encoding full-length hCAP18/LL-37 or cathelin-like domain alone were cloned into the pET 28a( þ ) expression vector system (Fig 1a) . This system generates fusion proteins with an N-terminal peptide of 5 kDa containing a His (6) puri¢cation tag. Through primer design, a sequence corresponding to an enterokinase cleavage site, pentapeptide (Asp)4 -Lys, was inserted after the fusion domain and before the cDNA of interest. Cultures of BL21 (DE3) bacteria transformed with either pET-hCAP18 or pET-Cath were then used for expression following IPTG induction. Over 70% of recombinant cathelin-like proteins were found in the soluble fraction. Only about 40% of full-length cathelicidin proteins were soluble, however. The remaining protein was found in the insoluble fraction. The expression of cathelicidin proteins with His-tag sequence at their N-terminus allowed for convenient puri¢cation from other soluble bacterial proteins using immobilized metal a⁄nity chromatography. Proteins were further puri¢ed to homogeneity using size exclusion chromatography. The purity of recombinant cathelin-like protein after elution was ¢rst checked by SDS-PAGE (Fig 1b) . A band of approximately 16 kDa, which corresponds to the cathelin-like region and the fusion sequence (5 kDa), was detected by Coomassie blue staining (Fig 1b) . The identity of the bands of expected size was con¢rmed by Western blot using antibodies against the cathelin-like domain (Fig 1c) . A single band of approximately 32 kDa was also detected that probably corresponds to a homodimer of cathelin-like protein. These results demonstrated the e¡ectiveness of the expression system used and recovery after puri¢cation (10^15 mg per l). Full-length hCAP18/LL-37 was identically puri¢ed and con¢rmed by identical techniques (data not shown). Cathelicidin proteins were removed from the N-terminal tag by cleavage with enterokinase. Optimization studies found that enterokinase treatment yielded complete cleavage when digestion was carried out at 371C overnight. No nonspeci¢c cleavage or degradation was observed during this period as con¢rmed by Coomassie blue staining of the gel (Fig 1c, lane 2) . Following enterokinase cleavage, cathelicidin proteins were further puri¢ed by size exclusion chromatography, fractions were analyzed by SDS-PAGE, and then identity and purity were con¢rmed by mass spectrometry (Fig 1d) . Approximately 50% of the preparations of recombinant cathelin-like protein displayed the expected peak at 11167.5 mass units by matrix-assisted laser desorption/ionization in agreement with theoretical mass and full disul¢de bond formation of this protein. To further con¢rm the identity of hCAP18/LL-37, the recombinant protein was treated with elastase to observe if this protein was processed similarly to the native cathelicidin. Elastase treatment generated a band migrating at the same size as synthetic LL-37, and a band at 14 kDa as seen by Western blot using anti-LL-37 antibodies (data not shown). This pro¢le is similar to that observed with the previously reported experiments on native human cathelicidins isolated from neutrophils and treated with elastase or proteinase 3 (Sorensen et al, 2001) . These experiments do not provide evidence of correct assembly of the disul¢de bridges of recombinant hCAP18, however.
Proteinase inhibitory activity To evaluate the possible protease inhibitory activity action of cathelin-like protein, the activity of human cathepsin L was measured in the presence or absence of recombinant cathelin-like protein using the £uorescent substrate Z-Phe-Arg-AMC. As shown in Fig 2, there was a linear relationship (R 2 ¼ 0.98^99) between the control (cathepsin L alone) and the test (cathepsin L þ cathelin-like protein). The generation of £uorescence was signi¢cantly decreased (slope ¼ 1.31 vs 0.71, respectively) when cathelin-like protein was added to the reaction. The hydrolytic activity of the cysteine proteinase cathepsin L was inhibited by 46% when cathelin-like protein was added at a ¢nal concentration of 10 À6 M. Parallel experiments with recombinant full-length hCAP18/LL-37 did not demonstrate inhibitory activity (data not shown).
Antimicrobial activity of recombinant cathelin-like protein Recombinant cathelicidins were tested for antimicrobial activity using a standard radial di¡usion assay. Di¡erent concentrations of the cathelin-like protein were loaded into wells on assay plates containing Gram-positive MRSA, S. epidermidis, and strains of the Gram-negative bacterial species E. coli, S. enteritidis, P. vulgaris, and P. aeruginosa. Cathelin-like protein had minimal inhibitory activity against growth of MRSA at 32 mM and E. coli at 16 mM, but did not inhibit growth of P. aeruginosa (Fig 3a) . Similarly, cathelin-like protein inhibited growth of S. epidermidis (32 mM) but not S. enteritidis or P. vulgaris. The full-length recombinant cathelicidin hCAP18/LL-37 did not demonstrate inhibitory activity against any of the bacteria tested, even at concentrations greater than 64 mM. In contrast to cathelin-like protein, the Cterminal peptide domains of the human and mouse cathelicidins (LL-37 and CRAMP, respectively) were inactive against the Gram-positive bacteria tested in this assay system, but were highly active against E. coli, P. aeruginosa, and S. enteritidis as previously described (Agerberth et al, 1995; Gallo et al, 1997; Turner et al, 1998; Bals et al, 1999) .
Next we investigated cathelin-like protein in a standard liquid phase AMP testing assay to validate the observed activities on agar (Fig 3b, c) . As LL-37 was active against E. coli but inactive against MRSA in the radial di¡usion assay, whereas cathelin-like protein was active against both, we chose these two bacteria for comparison of antimicrobial activity of full-length cathelicidin and its two distinct domains. With E. coli, addition of cathelinlike protein (16 mM) resulted in marked growth inhibition compared to the untreated controls, whereas LL-37 at 3 mM was bactericidal (Fig 3c) . With MRSA, an inverse pattern of activity was seen with cathelin-like protein and LL-37. Cathelin-like protein decreased MRSA CFU for the ¢rst 15 min and then was bacteriostatic, whereas LL-37 had no e¡ect even at 32 mM. Fulllength hCAP18/LL-37 (32 mM) did not show any activity against E. coli or MRSA (Fig 3b, c) . These results are consistent with those obtained in the radial di¡usion plate assay. Taken together, our results demonstrate that cathelin-like protein possesses inherent antimicrobial activity and suggest a novel role for this protein in host defense.
DISCUSSION
The expression of the cathelicidin gene product is an important determinant of resistance to infection in mammals (Nizet et al, 2001) . Heretofore, the antimicrobial activity of this molecule has been attributed to the action of the C-terminal peptide (in humans known as LL-37) after proteolytic processing of the precursor protein (in humans known as hCAP18/LL-37) to ''remove'' the N-terminal cathelin-like domain. The major goal of this study was to explore potential biologic function(s) of the evolutionarily highly conserved cathelin-like domain of human cathelicidin. We produced recombinant human cathelin-like protein and unprocessed full-length cathelicidin proteins in bacteria. These proteins were puri¢ed and characterized immunologically and physicochemically. Due to the complex structure of the cathelin-like domain, it was di⁄cult to obtain protein that was soluble. When soluble, however, functional analysis demonstrated that the recombinant cathelin-like domain possessed both antimicrobial and cysteine proteinase inhibitory activities. The cathelin-like protein caused inhibition of growth of some Gram-negative (E. coli) and Gram-positive (S. aureus) bacterial species. This activity was distinct from the known antimicrobial spectrum of the mature C-terminal peptide. Human cathelin-like protein also inhibited the action of the lysosomal cysteine proteinase cathepsin L. The recombinant full-length hCAP18/LL-37 cathelicidin lacked both activities before processing. Our ¢ndings suggest that the human cathelicidin gene encodes an inactive precursor (full-length hCAP18/LL-37) that, once processed by enzymes such as elastase or proteinase-3, generates two distinct antimicrobial molecules: cathelin-like protein and the mature LL-37 AMP. These data are distinct from an earlier study showing that native bovine proBac 5 isolated from bovine neutrophils can inhibit the activity of cathepsin L (Verbanac et al, 1993) . Bovine pro-Bac5 closely resembles the full-length hCAP18/LL-37 that was inactive in our experiments. Our data suggest that recombinant human cathelin-like protein alone is an inhibitor of cysteine proteinase cathepsin L. Lack of activity of the full-length protein may re£ect incorrect folding of our recombinant protein. Alternatively, the puri¢ed native pro-Bac5 previously reported may have contained undetectable amounts of cleaved cathelin-like protein that imparted activity.
Studies have reported that the lysosomal cysteine proteinase cathepsin L is present in in£ammatory cells, and may contribute substantially to tissue injury at in£ammatory lesions due to its potent elastinolytic and collagenolytic activities (Mason et al, 1986) . As cathelin-like protein is similar to cystatins, which are known to have diverse functions including the ability to inhibit cysteine proteinases, we tested recombinant cathelin-like protein for proteinase inhibitory action. Indeed, recombinant human cathelin-like protein was able to inhibit the proteolytic activity of the human cysteine proteinase cathepsin L. This phenomenon could be an evolutionary system designed to mitigate tissue injury and other potentially deleterious e¡ects of cathepsin L, and potentially other proteinases, released from lysosomes during in£ammatory responses. Moreover, several human pathogens secrete cysteine proteases that have been shown to play a role in disease pathogenesis, including SpeB and IdeS of Streptococcus pyogenes (Lukomski et al, 1999; von Pawel-Rammingen et al, 2002) , Lys-gingipain of Porphyromonas gingivalis (Kuboniwa et al, 2001) , and the extracellular cysteine proteases Ehcp1^6 of Entamoeba histolytica (Zhang et al, 2000) . Theoretically, the inhibition of such microbial virulence determinants may be another adaptive function of the cathelin-like domain in innate immune defense. Studies are under way to express su⁄cient quantities of recombinant cathelin-like protein in eukaryotic expression systems to determine the a⁄nity and inhibitory constant (K i ) with cathepsin L and a range of other cysteine proteases.
Mammalian cathelicidin is produced as an inactive precursor that is proteolytically cleaved inside activated neutrophils and at epithelial sites of in£ammation. Following this activation step, the active AMP and the cathelin-like domain with antimicrobial and cysteine protease inhibitor activities become available. Recent research has shown that granule proteases such as elastase and cathepsin each play important roles in neutrophil function and resistance to infection (Reeves et al, 2002) . It is possible that protease cleavage of full-length cathelicidin into two active antimicrobial agents is a critical step in the pathway to microbial killing (Cole et al, 2001) . The prosequence inhibition of cathepsin activity may represent a feedback loop to control the magnitude of local tissue degradation during the in£ammatory process. It remains to be determined whether cathelicidin prosequence inhibition of proteases in itself represents an antimicrobial property. Motifs involved in the interaction of cystatins with cysteine proteinases are not fully conserved in the cathelin-like domain, however. For example, glycine 9 (chicken cystatin numbering), a conserved residue found in all known sequences of inhibitory cystatins (Abrahamson et al, 1987; Ritonja et al, 1989) , is not present in cathelin-like protein. Another highly conserved sequence, QXVXG (residues 53^57), is also not present (Ritonja et al, 1989) , indicating that the interaction with cysteine proteinases is di¡erent. Overall, the proteinase inhibition activity of cathelinlike protein may be an alternative strategy of the host to control the regulation of its own enzymes and also to defend itself against microbe proteinases.
Next, we investigated the antimicrobial activity of the recombinant cathelin-like protein. Surprisingly, the results from these studies displayed antimicrobial activity at concentrations ranging from 16 to 32 mM against bacteria resistant to LL-37. Cathelin-like protein caused growth inhibition of both Gram-negative (E. coli) and Gram-positive (S. aureus) bacteria. We also observed that the parent hCAP18/LL-37 was inactive even at higher concentrations (464 mM), which is consistent with the previously reported data on rabbit and bovine cathelicidin precursors puri¢ed from tissue (Zanetti et al, 1991; Zarember et al, 2002) . In rabbit CAP-18, however, the unprocessed protein has shown synergistic antimicrobial activity when combined with the antimicrobial and lipopolysaccharide-binding protein BPI (Zarember et al, 2002) . The mechanism of this synergistic interaction is unknown. Further studies are required to determine the spectrum activity of cathelin-like protein and also to assess the minimal inhibitory activity required to eliminate these pathogens in vivo. In addition, experiments combining both cathelin-like proteins and LL-37 peptides are under way to test for the synergistic e¡ect of these two domains.
How the cathelin-like domain carries out its two distinct functions, antimicrobial and proteinase inhibition, is at present unknown. Many cationic and amphipathic peptides such as indolicidin (Falla et al, 1996) and magainins (Westerho¡ et al, 1989) exert their antimicrobial activity through membrane disruption and pore forming (Hancock, 1997) . Cathelin-like protein is not a basic protein, however, and therefore the mechanism of antimicrobial action is probably di¡erent from this class of peptides. One possibility is that cathelin-like protein has structural features that interact with the microbial membrane. Based on the proposed three-dimensional structure of the prosequence of the porcine protegrin-type cathelicidin (Sanchez et al, 2002a) , the N-terminus of this molecule presents an a-helical structure. This structure could be involved in the disruption of the normal function of microbial membrane. Furthermore, cystatins are similar to cathelin-like proteins (reviewed in Zaiou and Gallo, 2002) , are not basic proteins, and also show antibacterial and antiviral activity against a range of organisms (Takahashi et al, 1994; Blankenvoorde et al, 1998) . A synthetic peptide mimicking the cysteine proteinase inhibitory site of human cystatin C was found to kill S. pyogenes (Bjorck et al, 1989) . Secretory leukocyte protease inhibitor is a 12 kDa protein that also contains both serine protease inhibitory and antimicrobial activities (Ashcroft et al, 2000) . Recently, a cysteine proteinase inhibitor, designated L-cystatin, which is stored in the large granules of horseshoe crab hemocytes, was identi¢ed (Agarwala et al, 1996) . This molecule is 12,600 kDa, is similar to cystatin superfamily members, contains two disul¢de bridges at positions corresponding to the cathelin-like domain, and has shown antimicrobial activity against Gram-negative bacteria. These structural similarities support the function proposed for the cathelin-like protein. Furthermore, a recent investigation has solved the crystal structure of a homologous domain from the porcine cathelicidin protegrin-3 (Sanchez et al, 2002a) . These data con¢rm the similarity between cathelin-like proteins and cystatins, and also demonstrate potential homodimer formation for this protein as we observed in Fig 1(c) .
In summary, the ¢ndings of this study highlight a novel biologic function of cathelin-like protein as an antimicrobial protein in addition to its proteinase inhibitory activity. Recently, observations of cathelicidin in human sweat have shown the existence of cathelicidin processed to the expected size of the cathelin-like domain (Murakami et al, 2002) . Our data suggest that cathelin-like protein may play important roles not only in the protection of cells from unfavorable proteolysis by host and microbial cysteine proteases, but also in the direct killing or inhibition of invading pathogens. Several functions for the peptide C-terminal domain of the cathelicidin gene product have been discovered ranging from in£uencing proteoglycan expression, angiogenesis, and chemotaxsis to its antimicrobial e¡ects. This study now shows that the cathelin-like domain has multiple functions that can have complementary actions with the mature AMP in tissue defense (illustrated schematically in Fig 4) . A full knowledge of the function of the di¡erent domains of cathelicidin would be a valuable asset in understanding normal innate immune defense strategies in mammals and in attempts to design new antibiotics for use in treatment or prevention of infectious diseases. 
